Real-world study of sacubitril/valsartan for high blood pressure in UAE adults
Observes sacubitril/valsartan and single blood pressure medicines in adults with hypertension.
Plain-language title generated from the registry record
Registry title: A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
Key facts
- Where
- Abu Dhabi, Dubai, Fujairah, and Ras al-Khaimah, United Arab EmiratesSee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT07465666, who can take part
Where in United Arab Emirates
- Abu DhabiAbu Dhabi, United Arab EmiratesTaking people
- DubaiDubai, United Arab EmiratesTaking people
- FujairahFujairah, United Arab EmiratesTaking people
- Ras al-KhaimahRas al-Khaimah, United Arab EmiratesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT07465666
- Record updated
- 21 October 2026
- Original description
The aim of this study is to evaluate the real-world effectiveness of ARNi (sacubitril/valsartan) therapy and antihypertensive monotherapy in reducing blood pressure in hypertensive patients residing in the United Arab Emirates. Antihypertensive monotherapies will include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs).Read full original descriptionShow less
Real-world Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor (ARNi) Therapy in Lowering Blood Pressure in Hypertensive Patients in the United Arab Emirates
The aim of this study is to evaluate the real-world effectiveness of ARNi (sacubitril/valsartan) therapy and antihypertensive monotherapy in reducing blood pressure in hypertensive patients residing in the United Arab Emirates. Antihypertensive monotherapies will include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs).
Inclusion: Adult male or female patients (≥18 years); Patients with physician-diagnosed hypertension (as defined by international guidelines including the American Heart Association/American College of Cardiology [AHA/ACC] guidelines and/or the 2024 European Society of Cardiology [ESC] guidelines); Patients with documented office blood pressure ≥130/80 mmHg prior to initiating treatment (ARNi or monotherapy) or transitioning from monotherapy to ARNi; Patients who are either antihypertensive therapy naïve or currently receiving antihypertensive monotherapy (ACE inhibitor/ARB/CCB) with a physician-directed requirement to transition to ARNi; Note: Patients who transition from one monotherapy to another during the study are not eligible for inclusion; Patients willing to provide written informed consent to participate in the study.
Exclusion: Patients with malignant or severe hypertension (systolic blood pressure [SBP] ≥180 mmHg, diastolic blood pressure [DBP] ≥110 mmHg) at baseline; Patients with secondary causes of hypertension, as determined by the treating physician; Patients with a history of, or at risk of developing, angioedema; Patients with evidence of severe renal impairment (e.g., estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m\^2); Patients with serum potassium level ≥5.5 mmol/L at baseline; Pregnant or lactating women.